TABLE 4

Comparison Between PSMA PET-Guided sRT and Non–Image-Guided sRT Studies

		sRT dose to fossa (Gy)
Study	Patients (n)	Median	Range	sRT to pelvic lymph nodes	Median PSA before sRT (ng/mL)	Patients with ADT (%)	Guided by PSMA PET/CT	BRFS at 2 y
Stephenson et al. (26)	501	64.8	<59.4–>70	Yes (5% of patients)	0.72	17	No	<60%
Ervandian et al. (13)	259	69	66–74	No	NA	40.3	No	<70%
Goenka et al. (12)	285	NA	<70–≥70	Yes (7% of patients)	0.4	31	No	<65%
Stish et al. (27)	1,106	68	64.8–70.2	Yes (4% of patients)	0.6	16.3	No	<70%
Miyake et al. (28)	61	70		Yes (NA)	0.56	35.1	No	55%
Abugharib et al. (29)	657	68	59.4–72	Yes (NA)	0.4	24	No	<70%
Shipley et al. (2)	376	64.8		No	0.6	0^*	No	80%
Our study	90	66^†	59.4–70.2	Yes (20% of patients)	0.44	27.8	Yes	78%

↵* Study arm without ADT.
↵† 70 Gy (range, 67.2–72 Gy) to local recurrences.
NA = not available.
Shipley et al. (PSA nadir after sRT + 0.3 ng/mL) and Stephenson et al. (PSA nadir after sRT + 0.1 ng/mL or continuous PSA increase) defined BRFS differently from us.